Platinum Resistant

Question 1

Phase IIb, single-arm, open-label CONCERTO study investigating cedi + ola in non-gBRCAm pts with recurrent platinum-resistant OC who had received ≥3 previous lines of therapy for advanced OC: toxicity and RR?

Answer 1

60🧘‍♀️; median of 4 prior regimens;

Confirmed ORR 15.3%
Median PFS,* months 5.1
Median duration of response,*‡ months 8.3 5.6–10.3
Median overall survival, months 13.2

Question 2

Treatment Of FRα-Positive Platinum-Resistant Ovarian Cancer: FDA approval 11/2022

Answer 2

Antibody-Drug Conjugate Mirvetuximab Soravtansine

At the same time, the FDA approved the Ventana FOLR1 (FOLR1-2.1) RxDx Assay as a companion diagnostic to identify patients eligible for mirvetuximab.”

Question 3

Mirvetuximab ocular side effects?

Answer 3

Ocular: 59% of pts; median time to onset 5 wks:
11% grade 3 -
0.3% grade 4:

blurred vision, keratopathy, dry eye, cataract, photophobia, eye pain

Lubricating and topical steroids premedication

Opthalmology exam at baseline and every other cycle x 8c